glp 1 agonists and anesthesia GLP-1 receptor like semaglutide (Ozempic, Wegovy) tirzepatide (Mounjaro) have become incredibly common in diabetes and weight-management care, and they're now showing up more and more in the perioperative setting. These GLP-1 Agonists in Cardiovascular Diseases:

There are other important secondary outcomes, including the change in logMAR visual acuity, the development of center-involved diabetic macular edema (CI-DME) and the development of retinopathy, macular edema or vitreous hemorrhage requiring treatment

While early GLP1 drugs focused primarily on diabetes, newer agents, such as tirzepatidebased therapies, have gained traction in treating obesity, raising efficacy expectations and increasing competitive dynamics

What about heart and kidney protection

Cost considerations for researchers Cost is a practical factor that influences which compound researchers choose

Table 1 IBD and metabolic disorders are closely interconnected